Dialysis Mortality and Survival

This flow follows the evidence that HCV worsens survival in dialysis while also appearing to progress more slowly in the uremic environment.

increasingBearing stren­gth in each eventdecreasing

The Mortality Signal

The Mortality Signal A population risk Observational studies associate anti-HCV positivity with higher all-cause mortality among dialysis patients. Liver-related death is less frequent than other causes but markedly more common in infected patients. A broader burden The excess risk includes infection, cardiovascular disease, malnutrition, and impaired quality of life. HCV becomes a contributor to the whole dialysis prognosis rather than an isolated hepatic diagnosis.

Slower Liver Progression

Slower Liver Progression A paradox Compared with nonuremic controls, dialysis patients may show less inflammation, lower viral loads, and slower fibrosis progression. Some cohorts report surprisingly few cases of cirrhosis. Competing explanations Uremic immune dysfunction, viral adsorption by the dialyzer, and cytokine production during dialysis may blunt liver injury. The apparent protection does not erase the infection’s mortality burden.

The Survival Contradiction

The Survival Contradiction Better liver course yet worse survival HCV may progress slowly in the liver while still increasing overall mortality through cardiovascular and infectious pathways. The contradiction prevents clinicians from dismissing indolent liver findings. Clinical implication Patients require both liver surveillance and general risk reduction. A quiet aminotransferase profile cannot be treated as proof of a harmless infection.

late 1990s to 2007

during long-term dialysis follow-up

near the conclusion of dialysis studies